Satellos Bioscience (MSCL) Corporate presentation summary

Mission and scientific foundation

• Aims to restore natural muscle regeneration in Duchenne muscular dystrophy (DMD) and other muscle diseases, focusing on improving patient outcomes by targeting the underlying regenerative deficit.

• Founded in 2018, the company is in the clinical stage and listed on TSX and NASDAQ.

• Scientific approach is based on Dr. Michael Rudnicki’s discovery that DMD is primarily a disease of failed muscle regeneration.

Disease background and unmet need

• DMD affects 1 in 5,000 male births globally, with ~12,000 cases in the U.S., and is a fatal genetic disease with no approved therapies designed to regenerate muscle.

• Standard treatments have significant limitations, including toxic side effects and limited applicability based on genetic mutation.

• Muscle regenerative capacity in DMD drops sharply between ages 5-9, leading to progressive decline and premature death.

Mechanism of action and therapeutic approach

• Forazapadin (SAT-3247) is an oral, once-daily AAK1 inhibitor designed to restore muscle stem cell polarity and enable muscle repair and regeneration.

• Suitable for all DMD patients regardless of genetic mutation, with potential as a stand-alone or add-on therapy.

• Preclinical studies in canine models showed up to 4x increase in muscle strength and enhanced muscle regeneration.